证券日报网讯 1月30日，新华医疗在互动平台回答投资者提问时表示，公司历史上已累计承担/参与20 余项国家级科技项目，其中在"十二五""十三五""十四五"期间连续申报并获批国家重点研发计划，技术 与经验积淀深厚。"十五五"期间，公司将继续积极申报承担国家重点研发计划，聚焦医疗器械与制药装 备两大主业，围绕高端放疗影像、智慧感控、微创器械、高端制剂装备等方向，联合高校、医院及科研 院所，攻克"卡脖子"技术、推进国产化替代与前沿技术产业。 （编辑 姚尧） ...

Group 1 - Medpark held its first investment and financing meeting of 2026 at the Jiangsu Medical Device Technology Industry Park, inviting multiple investment institutions and bank representatives to facilitate deep integration between industry and capital [1] - The participating companies presented their technological advantages, core teams, market layouts, and financing plans during the roadshow, highlighting their strengths [3] - Suzhou HOPU ZhiYuan Biotechnology Co., Ltd. is a leading platform enterprise in sports medicine product R&D and production, with a research center in Suzhou and a production base in Changzhou, covering key areas such as sports medicine implants and minimally invasive devices [3] Group 2 - Suzhou Guoke Kangcheng Medical Technology Co., Ltd., incubated by the Suzhou Institute of Biomedical Engineering and Technology, focuses on "multi-modal + AI" intelligent diagnostic and therapeutic devices, providing integrated solutions for medical institutions and schools [3] - The event featured a presentation by Suzhou Rural Commercial Bank on financial policies to support enterprise financing, fostering active discussions on technological barriers, application scenarios, and financing needs [3] - Since last year, the Medpark investment and financing platform has established a regular service mechanism, conducting eight specialized matching activities and successfully hosting investment and financing meetings for the medical device and biopharmaceutical industries [4]